Pinned Tweet
Free, open source #thyroid risk stratification model for research. Anyone can create similar models without coding. Read our paper @EndoSocJournals link in comments @croendoyoung @Thyroid_ITS @TheEndoSociety @EndocrineToday @TIRO_expert @ETA_Thyroid @thyroid thyronaut.com/
1/ I built a free, open-source lab notebook that lives in your own GitHub. Created using @claudeai
Lab Notes for All: numbered, dated, signed pages that sync across phone, tablet and laptop, saved to your own private repo. 🧵
🤖 Made with AI
5/ Setup takes 5 steps, about 10 minutes: fork, turn on GitHub Pages, create a private repo, make a token, connect.
Free, MIT licensed:
github.com/johnyquest7/Lab-n…
Every experiment needs a lab notebook. Most apps lock your notes in, or charge monthly.
I built Lab Notes for All using Claude: free, open source, and your notes live in your own private GitHub repo. CSV charts, LaTeX, Jupyter, signed pages, works offline. github.com/johnyquest7/Lab-n…
Every experiment needs a lab notebook. Most apps lock your notes in, or charge monthly.
I built Lab Notes for All using Claude: free, open source, and your notes live in your own private GitHub repo. CSV charts, LaTeX, Jupyter, signed pages, works offline. github.com/johnyquest7/Lab-n…
@DrDatta_AIIMS what software do you use for taking lab notes?
Had a great time presenting at MID-ATLANTIC SOCIETY OF ENDOCRINOLOGISTS
2026 ANNUAL MEETING #EndoTwitter #AI #endocrinology
Smartphone photos show promise for predicting insulin resistance aaceendocrine.ai/videos/news…
Post GLP-1 weight gain - a potential solution? There is a vacuum in obesity care, and every clinician who prescribes these drugs sees it.
#GLP-1 therapies work while patients take them. When treatment stops, whether for cost, side effects, supply, pregnancy plans, or personal choice, most patients regain a large share of the weight. Yet we have no approved therapy whose specific job is weight maintenance after a GLP-1 is stopped.
The options today are limited: stay on the drug indefinitely, restart after regain occurs, rely on lifestyle support alone, or consider bariatric surgery in selected patients.
That empty space is exactly where Fractyl is aiming Revita.
Revita is a single endoscopic procedure that resurfaces the lining of the duodenum. The idea is to restore nutrient sensing and signaling that chronic metabolic disease disrupts, so the gut itself helps defend the lower weight after the drug is gone. No daily pills, no weekly injections, no implant.
In the REMAIN-1 pivotal cohort, Revita met its six-month co-primary endpoint on weight regain compared with a sham procedure (p=0.0023). Fractyl is now focusing the whole company on it, with an FDA De Novo submission planned for late 2026, 12-month data expected in early 2027, and a possible US authorization in late 2027.
The caveats matter. This is investigational in the United States, not FDA authorized. The results so far are company reported topline, not peer reviewed, and the headline release gives a p-value without the absolute difference in weight regain, which is the number clinicians actually need. Twelve-month durability is still unknown.
If the full data hold up, Revita would be the first procedural option built specifically for the post-GLP-1 maintenance gap, alongside continued drug therapy and surgery, not a replacement for them.
For now it is the clearest sign yet that the industry has noticed the vacuum: losing weight is no longer the only problem worth solving. Keeping it off after treatment stops is the next one. #obesity
globenewswire.com/news-relea…
Johnson Thomas, MD, FACE retweeted
Our MAI Diagnostic system is now 1.7x more accurate than physicians in the ED, even when they have access to the web to look things up.
It's also lower cost & does fewer medical tests to get to its diagnosis.
Published in the journal Science today...
What if we treated high glucose not by giving a drug, but by removing glucose itself?
A study in Science this week describes ECHO, an implantable device designed to do exactly that, without insulin and without medication.
How it works:
The implant sits under the skin and contains an electrocatalyst made of platinum decorated gold nanoclusters embedded in porous graphite.
When wirelessly powered at low power (0.75 volts), the catalyst selectively converts blood glucose into gluconate. Gluconate carries less energy and is cleared by the kidneys into the urine, so both glucose and calories leave the body.
Because the reaction is driven electrically, the rate of glucose removal is adjustable. Turn the current up, remove glucose faster. Turn it off, removal stops.
The closed loop comes from pairing it with a standard continuous glucose monitor. The CGM detects glucose above a set threshold, the implant activates, glucose falls, and the system switches off. In this study it was also smartphone controlled.
What happened in mice with type 2 diabetes and obesity:
Glucose returned to the normal range within 1 hour of activation. Repeated treatment maintained control for 6 weeks with no detectable hypoglycemia. As glucose was removed, metabolism shifted toward fat use. Body weight and triglycerides fell, while free fatty acids and ketone bodies rose. No adverse physiological, inflammatory, or behavioral effects were detected over those 6 weeks.
This is early stage, mice only, 6 weeks of data. Human questions are unanswered: catalyst durability over years, tissue reaction to a permanent implant, kidney handling of a sustained gluconate load, and whether the glucose removal rate scales from a mouse to a human.
We already have effective human therapies with outcome data, from metformin and SGLT2 inhibitors to GLP-1 receptor agonists and automated insulin delivery. ECHO is not a replacement for any of them today.
It is a proof of concept for a different category: closed loop diabetes care that does not deliver a drug at all, but removes the substrate itself. science.org/doi/10.1126/scie…
Does #menopause change how #obesity drugs work?
CagriSema: 25% weight loss in women, graded by menopausal stage (The Menopause Society meeting, Oct 20). Novo reported two post hoc analyses of REDEFINE 1. In 2,309 women, weekly CagriSema 2.4 mg (cagrilintide + semaglutide) was associated with 25.0% mean weight loss at 68 weeks vs 3.0% placebo; the full-trial read was 22.7%, below Novo's 25% target. A second post hoc (1,902 women) showed a pre/peri/post gradient: 26.7%, 24.8%, 23.1%. CagriSema is investigational, not cleared by FDA yet.
Successful health-care AI adoption depends on supporting clinicians’ work.
Panelists at Cleveland Clinic's AI Summit for Healthcare Professionals discuss workload, training, trust, and the risk of de-skilling.
Read more: aaceendocrine.ai/articles/20…
@JohnsonThomasMD
San Diego Is Calling! 🌊 #AACEAM2027 registration is LIVE.
📅 May 14–16 | Marriott Marquis San Diego Marina
✅ Earn up to 42 CME credits across plenaries, case-based sessions & hands-on workshops
✅ Deep-dive AI in Endo labs, Thyroid U/S skills training & Early Career workshops
✅ Network with leading clinician-scientists, journal editors & industry innovators
✅ First-Time Attendee reception & tailored meet-ups to supercharge your practice
💰 Save 25% with code SANDIEGO27 (ends Oct 23, 5:00 PM EDT)
🏨 Hotel open—$200 registration credit + special room rates
🎟️ Register now ➡️ 2027.aace.com/
#WeAreAACE
Veligrotug, a Full IGF-1 Receptor Antagonist, Produces Rapid and Durable Improvement in Active Thyroid Eye Disease: The THRIVE Phase 3 Trial - Johnson Thomas, 2026 journals.sagepub.com/doi/ful…
Johnson Thomas, MD, FACE retweeted
In our health workstream at Meta we did a project where we wanted to see what research papers medical experts could write using a Muse Wonder coding scaffold that could access a database of 5M electronic health records we licensed from a vendor. The goal is that with 5M patients in this database, AI could do research to answer arbitrary questions like “did people who take statin have higher rates of diabetes later in life”? The thing we were betting on here is on what happens when you put human experts, a strong coding model, and access to data all together
We worked with a small group of medical experts to help them use this AI tool and the punchline is that they all found that this setup enabled a much faster pace of health research. They generated ten manuscripts in around two weeks, with one researcher (Paddy Ssentongo) generating three. Throughout the process, they collaborated with each other to review manuscripts and write skill files to help our coding scaffold improve at doing research. The medical experts liked how quickly they could test different hypotheses and choose the best ones to continue working on
Health research is pretty unique in that it is super important to be able to interpret noisy data and have taste to know which variables are important, which was still a significant value add from human researchers. Given that medicine is one of the oldest fields in human history and it is ultimately about humans, keeping a substantial human component in this type of research is probably important. In the near future I see AI primarily as a tool to facilitate human-led research. With the right scaffold I believe health researchers can be 10x or even 100x more productive using AI tools that have appropriate access to the wealth of data that the world has collected about human health
One way to see this work is through the broader lens of AI for science. You can think of science as two parts: (1) collecting raw data about the world, and (2) synthesizing that raw data into understanding. In this project we already had existing data about the world and we aimed to accelerate part (2) using AI. Eventually, I imagine a world where we have such great AI tools that the time to synthesize raw data into understanding is driven towards zero. In that world, science will be substantially faster and most of the work will be focused on collecting the right raw data via physical experiments
We did this in a pretty short amount of time (which was the point) and I think the future of scientific research will be more faster and more exciting than ever
We’re exploring how AI can accelerate health science research.
While AI has made significant breakthroughs in formal sciences like mathematics, health data science depends on imperfect real-world data and consequential choices about cohorts, variables, and causal assumptions.
To explore how AI can assist health researchers, we built a human-led research scaffold powered by Muse Spark 1.3 and Muse Wonder with access to 5M retrospective de-identified electronic health records and publicly available data. A cohort of medical experts used the system to conduct original research, accelerate hypothesis generation, code execution, and manuscript drafting while maintaining full authority over scientific decisions.
Today, we’re sharing 10 research manuscripts produced through this exploration, spanning cardiology, oncology, infectious disease, emergency medicine, and more.
Read more in our research blog: go.meta.me/3U06wvD










